Mounjaro Weight Loss

Joinnextmed05 Jan, 2023Health

Mounjaro is an FDA-approved medication developed for management of type-2 diabetes. The drug was developed by Eli Lilly, one of the world?s largest pharmaceutical companies and released in June 2022. Eli Lilly, like Novo Nordisk, specializes in the development of drugs called GLP-1?s, which have been shown to work well in managing insulin levels in type-2 diabetics. Eli Lilly developed the drug Trulicity, based on a molecule called ?dulaglutide.? They discovered that in overweight or obese diabetic patients, these drugs curbed appetites and led to remarkable weight loss properties. Mounjaro is a dual GIP and GLP-1 receptor agonist that improves clinical outcomes beyond those achieved by GLP-1 agonists.